Click for new scientific resources and news about Corona[COVID-19]

Paper Information

Journal:   RAZI JOURNAL OF MEDICAL SCIENCES (JOURNAL OF IRAN UNIVERSITY OF MEDICAL SCIENCES)   SEPTEMBER 2011 , Volume 18 , Number 87; Page(s) 8 To 13.
 
Paper: 

EVALUATION OF PENTOXIFYLLINE EFFECT IN TREATMENT OF ANKYLOSIS SPONDYLITIS PATIENTS REFERRED TO RASOOL-E-AKRAM HOSPITAL

 
 
Author(s):  SHIRANI FATEMEH*, SEBT ROZATI SEYED MEHDI*
 
* ISFAHAN UNIVERSITY OF MEDICAL SCIENCES, ISFAHAN, IRAN
 
Abstract: 

Background: Ankylosing spondylitis (AS) is a spondyloarthropathy of unknown etiology, with widespread effect on axial and peripheral skeleton. The aim of this study was determination of pentoxifylline effect on Bath Ankylosing spondylitis Disease Activity Index (BASDAI) of uncontrolled AS patients in Rasool-e-Akram Hospital Rheumatology Clinic.
Methods: This pilot study was performed on 30 patients with ankylosis spondylitis with BASDAI
³4 ignoring their previous medical treatments. The patients received Pentoxifylline tablets 400 mg TDS and then evaluated 6 and 12 weeks after the treatment. Data were analyzed by Paired T test and p<0.05 was considered to be significant.
Results: 30 patients (26 males (86.7%), 4 females (13.3%)) with ankylosing spondylitis were evaluated. Mean age of patients was 32.42±8.14. Mean±standard deviation of BASDAI was 6.53±1.72 prior to the treatment, which decreased to 5.17±1.58 after 6 weeks and 4.88±1.66 after 12 weeks of treatment (p=0.000). The differences of BASDAI before and after treatment with pentoxifylline were significant.
Conclusion: Pentoxifylline can be advised for uncontrolled AS patients regardless of current or previous treatment.

 
Keyword(s): ANALYZING SPONDYLITIS, BASDAI (BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX), PENTOXIFYLLINE
 
References: 
  • ندارد
 
  Persian Abstract Yearly Visit 85
 
Latest on Blog
Enter SID Blog